Pathogenesis of cardiovascular disease in HIV infection

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 234-239

  Carr, Andrew ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; HIV; Pathogenesis

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LONG TERM CARE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VIROTHERAPY;

EID: 42049098428     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fb7be0     Document Type: Review

References (50)

1. Grinspoon SK, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
2. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
3. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
4. Shahmanesh M, Das S, Stolinski M, Shojaee-Moradie F, et al. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab 2005; 90:755-760.
5. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
6. Umpleby AM, Das S, Stoliski M, et al. Low density lipoprotein apolipoprotein B metabolism in treatment-naïve HIV patients and patients on antiretroviral therapy. Anti Ther 2005; 10:663-670.
7. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:1423-1427.
8. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90:154-162.
9. Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96. A randomized trial demonstrated an increased risk of cardiovascular disease with intermittent antiretroviral therapy. The mechanism remains unexplained.
10. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS 2001; 15:2407-2414.
11. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153-160.
12. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract]. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver. Alexandria: CROI; 2006. http://www.retroconference.org/2006/Abstracts/ 27965.htm. [Accessed 19 October 2007].
13. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365. This paper describes in-vitro data that suggest a new mechanism by which HIV infection might directly lower levels of HDL cholesterol.
14. Neaton J. Changing patterns of morbidity and mortality in HIV disease [abstract]. In: Abstracts of the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney. Geneva: IAS; 2007. Abstract MOSY202. http://www.ias2007.org/pag/PSession.aspx?s=18 [Accessed 8 January 2008].
15. Tello-Montoliu A, Marín F, Roldán V, et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 2007; 262:651-658.
16. Hommes MJ, Romijn JA, Endert E, et al. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40:651-656.
17. Matzen K, Dirkx AEM, Oude Egbrink MGA, et al. HIV-1 tat increases the adhersion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res 2004; 104:145-155.
18. 3 as a target for blocking HIV-1 tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2005; 25:2315-2320.
19. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 2006; 185:1-11.
20. DAD Study Group. Class of antiretroviral drug and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735. This paper reports that only about half the protease inhibitor effect on myocardial infarction risk appears to be associated with changes in cholesterol and triglyceride levels.
21. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350:1220-1234.
22. Carr A, Emery SE, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
23. Das S, Shahmanesh M, Stolinski M, et al. In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 2006; 49:538-542.
24. Riddle TM, Fichtenbaum CJ, Hui DY. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J Acquir Immun Defic Syndr 2003; 33:564-570.
25. Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006; 91:2605-2611. This paper reports that administration of leptin led to a substantial reversion of insulin resistance in lipoatrophic adults, suggesting that lipoatrophy is a dominant cause of insulin resistance in HIV-infected patients receiving antiretroviral therapy.
26. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51:3163-3169.
27. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vase Biol 2000; 20:2625-2629.
28. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7:1327-1331.
29. Riddle TM, Schildmeyer NM, Phan C, et al. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res 2002; 43:1458-1463.
30. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
31. Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-1 protease modulates proteasome activity. J Biol Chem 1999; 274:35734-35740.
32. Petit JM, Duong M, Florentin E, et al. Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study. J Lipid Res 2003; 44:1692-1697.
33. Lenard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000; 47:121-129.
34. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
35. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6:421-425.
36. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
37. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
38. th IAS Conference on HIV Pathogenesis, treatment and Prevention. 22-25 July 2007, Sydney. Geneva: IAS; 2007. Abstract TUPEB072. http://www.ias2007.org/pag/PosterExhibition.aspx?presType=PE&day= 24&Track=All&absCat= Lipodystrophy%2c+metabolic+abnormalities%2c+cardiovascular+disease. [Accessed 8 January 2008].
39. Xu A, Yin S, Wong L, et al. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrin 2004; 145:487-494.
40. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-20254.
41. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
42. Blumer RME, van Vonderen MGA, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008; 22:227-236. The authors provide prospective evidence that insulin resistance may be more likely with the nucleoside analogue than with ritonavir-boosted lopinavir, a protease inhibitor.
43. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003; 111:389-397.
44. Muteanu A, Zingg JM, Ricciarelli R, Azzi A. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by α-tocopherol. Free Rad Biol Med 2005; 38:1047-1056.
45. Zhou H, Pandak WM, Lyall V, et al. HIV protease inhibitors activate the unfolded protein response in macrophages: Implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005; 68:690-700.
46. Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immun Defic Syndr 2005; 40:12-19.
47. Chai H, Yan S, Lin P, et al. Curcumin blocks HIV protease inhibitors ritonavir-induced vascular dysfunction in porcine coronary arteries. J Am Coll Surg 2005; 200:820-830.
48. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005; 38:147-155.
49. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292:E1666-E1673. The authors provide direct evidence that a nucleoside analogue reverse transcriptase inhibitor can inhibit mitochondrial function and induce insulin resistance in vivo.
50. Bradshaw EL, Li XA, Guerin T, et al. Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C. Am J Physiol Cell Physiol 2006; 291:1271-1277.